Allergan Announces Quarterly Conference Call.

IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) invites you to listen to David Pyott, Chairman of the Board, President and Chief Executive Officer, and Jeff Edwards, Executive Vice President, Finance and Business Development, Chief Financial Officer, discuss the Company's 2005 fourth quarter results on Thursday, February 2, 2006. If Allergan has not received antitrust clearance from the Federal Trade Commission (FTC) in connection with the acquisition of Inamed Corporation (NASDAQ:IMDC) and the pending exchange offer for all outstanding Inamed common stock has not been completed by February 2, 2006, the conference call will only report on Allergan's 2005 actual results and will include limited 2006 guidance. Allergan intends to communicate additional 2006 guidance for the combined company following FTC clearance of the acquisition and the completion of the exchange offer.

The live Web cast can be accessed through the Allergan Web site, www.allergan.com, beginning at 8:00 a.m. Pacific Time. A replay of the discussion will be available soon after the call and can be accessed through www.allergan.com, 1-866-397-1425 for domestic locations, or 1-203-369-0532 for international locations. A passcode will not be required. The replay will be available for one week following the live call.

It is Allergan's policy to comply fully with Regulation FD. Therefore, Allergan intends to utilize these Web-casted events to discuss financially oriented goals and objectives and to disclose material Company and industry-based topics in an open manner. The Company does not plan to report or comment on its progress during the current fiscal quarter. Any statement made by others with respect to progress mid-quarter cannot be attributed to the Company. During a quarter, the Company's commentary will be limited to discussions of public information, such as historic financial performance, and matters that are deemed to be immaterial. Allergan will make no comments with respect to market rumors or speculation.

Forward-Looking Statements

This press release contains "forward-looking statements", including, among other statements, statements regarding the proposed business combination between Allergan and Inamed. These statements are based on current expectations, but are subject to certain risks and uncertainties, including that required regulatory approvals will not be obtained in a timely manner, if at all; and that the proposed transaction will not be consummated. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered.

Additional Information

Allergan has filed a Registration Statement on Form S-4 and a Tender Offer Statement on Schedule TO in connection with the exchange offer. Inamed stockholders should read those filings, and any other filings made by Allergan with the SEC in connection with the proposed Inamed acquisition, as they contain important information. These SEC filings, as well as Allergan's other public SEC filings, can be obtained without charge at the SEC's Web site at www.sec.gov, and at Allergan's Web site at www.Allergan.com.